Protalix BioTherapeutics (PLX) Retained Earnings (2010 - 2025)

Protalix BioTherapeutics' Retained Earnings history runs 16 years deep, the most recent figure standing at -$385.0 million for Q4 2025.

• On a quarterly basis, Retained Earnings fell 1.75% year-over-year to -$385.0 million in Q4 2025; TTM through Dec 2025 was -$385.0 million, a 1.75% decrease from a year earlier, with the FY2025 full-year figure at -$385.0 million, down 1.75% from the prior year.
• Retained Earnings declined to -$385.0 million in Q4 2025 per PLX's latest filing, from -$378.4 million in the prior quarter.
• Across five years, Retained Earnings topped out at -$374.9 million in Q4 2021 and bottomed at -$389.9 million in Q4 2022.
• The 5-year median for Retained Earnings is -$381.5 million (2023), against an average of -$381.9 million.
• Across the five-year window, Retained Earnings fell 7.94% in 2021 and gained 2.13% in 2023, its largest moves.
• Year by year, Retained Earnings stood at -$374.9 million in 2021, then decreased by 3.98% to -$389.9 million in 2022, then advanced by 2.13% to -$381.5 million in 2023, then advanced by 0.83% to -$378.4 million in 2024, then slipped by 1.75% to -$385.0 million in 2025.
• Per Business Quant, the three latest PLX Retained Earnings figures stand at -$385.0 million (Q4 2025), -$378.4 million (Q4 2024), and -$381.5 million (Q4 2023).